Key Facts

PIPS Key Facts
Active Substance
Active Substance:
  • gantenerumab
Invented Name
Not available at present
PIP Number MHRA-100309-PIP01-21
Pharmaceutical form(s)
Pharmaceutical form(s):
  • All pharmaceutical forms
Therapeutic area
Therapeutic area:
  • Neurology
Conditions / Indications
Conditions / Indications:
  • Prevention of Alzheimer's disease
Route(s) of administration
Route(s) of administration:
  • Subcutaneous use
PIP applicant
  • Roche Products Limited
  • Country United Kingdom
  • Tel 07824821881
  • Email
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

PIPS Decision Documents
Decision Document Decision Document on a Paediatric Investigation Plan (PIP):gantenerumab.pdf
Published Date 19/05/2022